REMICADE for RA
How REMICADE Can Change the Course of Your Rheumatoid Arthritis (RA)
Treat the Underlying Cause of Joint Damage — Not Just the Symptoms
Although it may not be evident to you, the ongoing pain, stiffness, and swelling you experience from your RA could suggest serious damage occurring to your joints. So, it’s important that you’re on an effective treatment that goes beyond just treating your symptoms to help stop further joint damage as quickly as possible.
Treatment with REMICADE Can Change the Course of Your RA
If you have been diagnosed with moderate to severe
rheumatoid arthritis, REMICADE may be able to help. In combination with methotrexate, REMICADE:
- Helps stop further joint damage. And, for some patients without joint damage, it may help stop damage before it starts.
- Can improve your mobility by helping you do everyday activities, such as getting out of bed, dressing yourself, washing, and walking.
- Quickly relieves pain and stiffness — in as little as two weeks for many patients.
- Provides infrequent dosing that is customized according to your weight. REMICADE is given as a two-hour IV infusion by a healthcare professional. You may need REMICADE only once every eight weeks. That could be as few as six times per year.
- Has been used
to treat more than one million patients worldwide with conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn’s disease in adults, pediatric Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.
- REMICADE is covered by most insurance plans including commercial insurers, Medicare, and Medicaid. Coverage policies may vary by insurers or even between plans offered by the same insurer. If you have any questions about insurance coverage or reimbursement, you should first call your insurance company or Medicare. If you have any questions or concerns, or if you need additional information related to medical coverage or patient assistance for REMICADE, you may call AccessOneSM toll-free at 1-888-ACCESS-1 (222-3771) for assistance.
For further information about studies involving treatment with REMICADE, please visit the following resource:
|